Associations of the gut, cervical, and vaginal microbiota with cervical cancer: a systematic review and meta-analysis

• Published in: BMC women's health Vol. 25; no. 1; pp. 65 - 13
• Main Authors: Wen, Qin, Wang, Shubin, Min, Yalan, Liu, Xinyi, Fang, Jian, Lang, Jinyi, Chen, Meihua
• Format: Journal Article
• Language: English
• Published: London BioMed Central 15.02.2025; BioMed Central Ltd; BMC
• Subjects: 16S rRNA sequencing; Breast cancer; Cervical cancer; Cervical microbiota; Cervix; Cervix Uteri - microbiology; Colorectal cancer; Development and progression; Dysbiosis; Female; Gastrointestinal Microbiome - physiology; Gastrointestinal system; Gut microbiome; Gynecology; Health aspects; Human papillomavirus; Humans; Immunotherapy; Infections; Lung cancer; Maternal and Child Health; Medicine; Medicine & Public Health; Meta-analysis; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Physiological aspects; Quality of life; Relative abundance; Reproductive Medicine; Risk assessment; Systematic Review; Uterine Cervical Neoplasms - microbiology; Vagina; Vagina - microbiology; Vaginal microbiota; Vaginal mucosa; China; 16S rRNA sequencing; Dysbiosis; Vaginal microbiota; Gut microbiome; Cervical cancer; Cervical microbiota; Meta-analysis
• ISSN: 1472-6874; 1472-6874
• DOI: 10.1186/s12905-025-03599-1

Background An increasing number of studies indicate that the gut, cervical, and vaginal microbiota may play crucial roles in the development of cervical cancer (CC). However, the interactions between the microbiota and the host are yet unknown. To address this gap, a systematic review and meta-analysis were conducted to assess the microbiota alterations in a variety of body locations, including the gut and genital tract. Methods Electronic searches of PubMed, Embase, Web of Science, and the Cochrane Library were conducted to retrieve eligible papers published from January 1, 2014, to January 1, 2024 (PROSPERO: CRD42024554433). This study was restricted to English-language studies reporting on alpha diversity, beta diversity, and relative abundance, as well as on patients with CC whose microbiota had been analyzed via next-generation sequencing technologies. To assess the risk of bias (RoB), we utilized the Newcastle‒Ottawa Quality Assessment Scale (NOS) and the ROBINS-I tool. For the meta-analysis, we employed Review Manager 5.4. Results Thirty-six eligible studies were included in this review. The Chao1 index (SMD = 0.96, [95% CI: 0.71, 1.21], I 2  = 0%) and the Shannon index (SMD = 1.02, [95% CI: 0.53, 1.50], I 2  = 85%) values from vaginal samples were significantly greater in patients than in the controls. In the cervical samples, the Shannon index value (SMD = 1.29, [95% CI: 0.61, 1.97], I 2  = 93%) significantly increased, whereas the Chao1 index value did not significantly differ (SMD = 0.50, [95% CI: -0.46, 1.46], I 2  = 89%). The Shannon index value (SMD = 0.25, [95% CI: -0.22, 0.72], I 2  = 38%) did not significantly differ across the gut samples. The majority of studies (19/25) indicated that the patients and noncancer controls differed significantly in terms of beta diversity. Cancer-associated changes were observed, with a dramatic decrease in the Lactobacillus genus and significant increases in pathogenic bacteria, including the Anaerococcus , Peptostreptococcus , Porphyromonas , Prevotella , and Sneathia genera. Additionally, the impact of antineoplastic therapies on microbial diversity was inconsistently reported across several studies. Conclusion This systematic review elucidates the microbiota alterations associated with the prevalence of CC and its response to anti-tumor therapies, aiming to provide insights for future research directions and precision medicine strategies to enhance women’s quality of life. Prospero registration CRD42024554433.